• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Studies Support Use of Daily Antibiotic to Prevent STDs in High-Risk Groups

Medically reviewed by Carmen Pope, BPharm. Last updated on July 19, 2024.

By Ernie Mundell HealthDay Reporter

FRIDAY, July 19, 2024 -- It's long been known that popping the antibiotic doxycycline within 72 hours of a risky sexual encounter can greatly reduce a person's risk for a sexually transmitted infection (STI).

In fact, the U.S. Centers for Disease Control and Prevention formally recommended this type of "morning after" strategy last month.

But what if folks at especially high risk for STIs simply took "doxy" daily -- similar to how some people now take HIV meds as pre-exposure prophylaxis (PrEP) to prevent that infection?

Two small new studies suggest that this so-called "DoxyPrEP" strategy may indeed keep STIs at bay.

Both reports are scheduled to be presented next week at the 25th International AIDS Conference in Munich.

One study involved 52 gay or bisexual Canadian men living in Toronto and Vancouver. All of the men were living with HIV, and they also had a past history of contracting a common STI, syphilis.

For 48 weeks, the men were randomly divided into two groups: One group took a 100-milligram pill of doxycycline daily, while the other took a "dummy" placebo pill. Overall, 41 of the 52 men completed the trial.

In the group that got doxycycline daily, rates of new syphilis infections fell by 79%, reported study co-author Dr Troy Grennan, of the British Columbia Centre for Disease Control.

Rates of two other common STIs also declined for the men on DoxyPrEP: gonorrhea infections fell by 68% and chlamydia infections dropped by 97%, Grennan and colleagues reported.

The second study involved another group at higher risk for STIS: sex workers.

The study tracked outcomes for 40 female sex workers in Tokyo. All were provided with daily 100 mg doses of doxycycline and followed over time.

Rates of STIs declined dramatically, according to study co-author Seitaro Abe, of Japan's National Center for Global Health and Medicine. Overall, the incidence of any new STI fell from about 232 per 100 person-years (a measure of the time an individual is tracked during a study) to 79 per 100 person-years.

The biggest improvement among the women occurred for syphilis, which declined to zero for those taking DoxyPrEP. Rates of chlamydia declined slightly and there was no difference seen when it came to the incidence of gonorrhea.

There may have been mental health benefits, as well: Nearly three-quarters of the women in the study said their fear of contracting an STI fell considerably while taking DoxyPrEP.

As to side effects, 22.7% of participants in the Tokyo study did report some nausea and/or vomiting, but otherwise there were no serious side effects from daily doxycycline use.

Abe's team believes the findings support the use of DoxyPrEP in at-risk populations.

However, larger trials may be needed, and because these findings are being presented at a medical meeting, they should be considered preliminary till published in a peer-reviewed journal.

For more information see Doxycycline for STDs.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.